Follicular Lymphoma Clinical Trial
Official title:
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies. The ACE1831-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and efficacy of ACE1831 in patients with CD20-expressing Non-Hodgkin lymphoma.
Status | Recruiting |
Enrollment | 42 |
Est. completion date | September 2027 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - CD20-positive B-cell NHL that is persistent or progressive after having received at least 2 prior systemic therapies per NCCN guidelines - At least 1 measurable lesion according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma - Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 - Adequate hematologic and renal, hepatic, and cardiac function - Oxygen saturation via pulse oxygenation = 92% at rest on room air Key Exclusion Criteria: - Prior treatment with a genetically modified cell therapy product targeting CD20 - Autologous stem cell transplant within 6 weeks of informed consent or history of allogeneic stem cell transplantation - History of central nervous system (CNS) lymphoma or primary CNS lymphoma - History or presence of clinically relevant CNS disorder (e.g. epilepsy) - Clinically significant active infection - Currently active, clinically significant cardiovascular disease - Human Immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection - History of other malignancies with the exception of certain treated malignancies with no evidence of disease - Primary immunodeficiency disorder - Pregnant or lactating female - Any medical, psychological, familial, or sociological conditions that, in the opinion of the Investigator or Sponsor Medical Monitor, would impair the ability of the subject to receive study treatment, comply with study requirements, or understanding of the informed consent |
Country | Name | City | State |
---|---|---|---|
Taiwan | Tamsui MacKay Memorial Hospital | New Taipei City | |
Taiwan | Linkou Chang-Gung Memorial Hospital | Taoyuan City | |
United States | Emory University | Atlanta | Georgia |
United States | The University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | Indiana University Simon Comprehensive Cancer Center | Indianapolis | Indiana |
United States | Norton Cancer Institute | Louisville | Kentucky |
United States | AdventHealth Orlando | Orlando | Florida |
Lead Sponsor | Collaborator |
---|---|
Acepodia Biotech, Inc. |
United States, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Pharmacodynamics of ACE1831 | Serum levels of interferon-?, TNF-a, IL-2, IL-6, IL-8 and IL-10, as well as other potential biomarkers | 2 years | |
Primary | Incidence of adverse events (AEs), Dose Limiting Toxicities (DLTs), adverse events of special interest (AESIs), and serious adverse events (SAEs) | 2 years | ||
Primary | Change from baseline in ECOG status | 1 year | ||
Primary | Change from baseline in physical examination results | Number of subject with change from baseline clinically significant physical examination findings by dose level (descriptive) | 1 year | |
Primary | Change from baseline clinical laboratory tests results | Number of subjects with change from baseline clinically significant lab findings by dose level (descriptive) | 1 year | |
Primary | Change from baseline in urinalysis results | Number of subjects with change from baseline clinically significant urinalysis findings by dose level (descriptive) | 1 year | |
Primary | Change from baseline in vital signs results | Number of subjects with change from baseline clinical significant vital signs findings by dose level (descriptive) | 1 year | |
Primary | Change from baseline in electrocardiogram (ECG) results | Number of subjects with change from baseline clinically significant ECG findings by dose level (descriptive) | 1 month | |
Primary | Maximum Tolerated Dose (MTD) | 1 month | ||
Secondary | Persistence of ACE1831 after administration | Half-life of ACE1831 | 1 month | |
Secondary | Measure of anti-ACE1831 antibodies after administration | Titration of anti-ACE1831 antibodies after administration | 1 month | |
Secondary | Objective Response Rate (ORR) | Objective response of each patient's underlying lymphoma, duration of response, and progression-free survival all based on the revised IWG Response Criteria for Malignant Lymphoma | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT03676504 -
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03078855 -
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
|
Phase 3 | |
Active, not recruiting |
NCT03245021 -
Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A
|
Phase 1 | |
Recruiting |
NCT05365659 -
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082936 -
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02213263 -
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
|
Phase 3 | |
Completed |
NCT01691898 -
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 1/Phase 2 | |
Terminated |
NCT03585725 -
A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma
|
Early Phase 1 | |
Terminated |
NCT00772668 -
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
|
N/A | |
Recruiting |
NCT02892695 -
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
Terminated |
NCT02204982 -
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
|
Phase 3 | |
Terminated |
NCT00850499 -
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
|
Phase 2 | |
Completed |
NCT02536664 -
Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants
|
||
Terminated |
NCT00475332 -
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
|
Phase 2 | |
Terminated |
NCT00136591 -
A Phase 2 Study of Velcadeā¢ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT06068881 -
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
|
Phase 2 | |
Completed |
NCT04034056 -
Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)
|